Foghorn cuts 40% of staff after FHD-909 trial falls short

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Foghorn cuts 40% of staff after FHD-909 trial falls short

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

October 1, 2026 7:00 AM EDT

Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program

Company to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platform

Pipeline prioritization and organizational changes expected to extend cash runway into the second half of... More